Statistical Comparison (P values) of CDR3 Lengths of TCR β Chains Using Different V Genes in CLL Patients (n = 10) and Age-Matched Healthy Controls (n = 9)
| BV Genes . | CD4+ Subset . | CD8+ Subset . |
|---|---|---|
| BV2 | .2352 | .1768 |
| BV3 | .2758 | .1819 |
| BV4 | .00414-150 | .00624-150 |
| BV5S1 | .0616 | .02604-150 |
| BV6S1-3 | .00214-150 | .00604-150 |
| BV7 | .8340 | .00534-150 |
| BV8 | .00124-150 | .04644-150 |
| BV9 | .01684-150 | 4-151 |
| BV Genes . | CD4+ Subset . | CD8+ Subset . |
|---|---|---|
| BV2 | .2352 | .1768 |
| BV3 | .2758 | .1819 |
| BV4 | .00414-150 | .00624-150 |
| BV5S1 | .0616 | .02604-150 |
| BV6S1-3 | .00214-150 | .00604-150 |
| BV7 | .8340 | .00534-150 |
| BV8 | .00124-150 | .04644-150 |
| BV9 | .01684-150 | 4-151 |
BV genes included in the calculations were selected based on the data in Table 3.
Statistically significant differences comparing the CDR3 lengths of the CLL patients and the control donors, with a skew towards a more polymorphic CDR3 length pattern in the control donors.
No TCRBV overexpression was found.